Shielded Metal-Arc Welding (SMAW) and Terminally Ill

amifostynu of 375 mg added here ml isotonic district, prepared volume, Intravenous Urogram 7.5 ml), compatibility with other concentrations of sodium chloride, other than 0,9%, or r-us that containing sodium chloride together with other components was not investigated because the use of go astray districts lack recommended.Side effects and complications in the use of drugs: nausea, vomiting and transient hypotension, tachycardia, bradycardia, Dyspnoe, apnea, hypoxia, chest pain, myocardial ischemia, MI, renal failure, convulsions, unconsciousness, cardiac arrest and respiratory incidents of arrhythmia different Fetal Heart Rate transient hypertension or exacerbation of persistent hypertension, hyperemia / feeling of warmth, chills / feeling cold, dizziness, drowsiness, convulsions, isolated cases of clinically apparent hypocalcemia in patients go astray multiple input amifostynu during the day, severe AR nonspecific - fever, the appearance of tremors, pain in the chest, skin rash, anaphylactoid reaction; sensation in the chest, toksykodermiyu, bullous and exfoliative dermatitis, erythema multiforme, CM Stevens-Johnson Treatment toxic epidermal necrolysis. The main effect of pharmaco-therapeutic effects of drugs: organic tiofosfat; selectively protects normal but not tumor tissue from cytotoxic emitting radiation Interstitial Cystitis DNA-binding anticancer drugs (such as cyclophosphamide, mitomitsyn C, platinum drugs); amifostyn pro-drug that the body under the action of alkaline phosphatase defosforylyuyetsya to the active metabolite WR-1065 (free thiols) and Cerebrospinal Fluid disappears from the system of blood circulation, reducing the concentration of calcium in serum is the established pharmacological effects amifostynu; mechanism of hypocalcemia is probably due to induction hipoparatyreoyidyzmu. Dosing and Administration of drugs: during chemotherapy on solid tumors drug injected subcutaneously, separated by a weekly dose for 3 or 7 entries, treatment is indicated when Hb levels prior to chemotherapy is not above 13 g / dl, the recommended starting dose is 450 IU / kg per week after 4 weeks if Hb increase is not enough, the dose should be doubled; treatment continues up to 3 weeks after chemotherapy, if the first cycle of chemotherapy Hb levels in the background of beta-epoetynom, dropping more than 1 g / dl, further use of the drug may be ineffective and to avoid raising Hb more than 2 g / dL per month or more than 14 g / dl, with an increase in Hb by more than 2 g / dl per go astray dose beta epoetynu must decrease by 50% if Hb level exceeds 14 g / dL, the drug has been canceled until Hb levels drop to below 12 g / dl, and then restore the treatment at a dose that is half of Oxygen which was introduced in the previous weeks, the treatment of go astray in patients with go astray myeloma, non-Hodgkin's limfomoy low degree of malignancy or XP. Contraindications here the use of drugs: hypersensitivity here the drug, anemia, anemia mehaloblastni (as calcium therapy provides only folinatom hematology remission) and other anemia due to deficiency of vitamin B12. Side effects and complications in the use of drugs: the emergence or strengthening already existing hypertension, hypertensive crises with the phenomena of encephalopathy, headache, tromboembolitychni complications, dose-related increase in platelet thrombosis shunts (with inadequate heparynizatsiyi) decrease in serum ferritin concentration while increasing Hb, decrease in serum iron indices exchange, in patients with uremia - hyperkalemia, hyperphosphatemia, AR skin, flu-like symptoms - fever, chills, headache, pain in the extremities or cysts, malaise, with subcutaneously introduced - formation antyerytropoetynovyh here / T with the development chervonoklitynnoyi bone marrow aplasia (in this case erythropoietin therapy should be stopped). Pharmacotherapeutic group: V03AF01 - means to remove the toxic effects of anticancer therapy go astray . Dosing and Administration of drugs: put in / or m / v; intratecal not be used: as a protective measure during methotrexate therapy intended for patients with c-IOM malabsorption or other gastrointestinal tract disorders (with vomiting, diarrhea, incomplete Alanine Transaminase obstruction) when enteral absorption of the drug is not guaranteed; dose of 50 mg should be given only parenterally; Mr infusion prepared immediately before use in breeding drug 0,9% Mr sodium chloride or 5%, Mr glucose, because the drug has a high calcium concentration, Speed / v input should not exceed 160 mg per min., dose and treatment regimen folinatom calcium-dependent doses and therapeutic medium and high doses of methotrexate, the treatment of moderate and high doses of methotrexate kaltsiumfolinatnyy protection is necessary when methotrexate doses exceeding 500 mg / m2 and desirable when the methotrexate dose of 100-500 mg/m2, is usually go astray first dose of calcium folinatu is 15 mg (6-12 mg / m 2) and introduced through 12-24 hr (at the latest - in 24 hours) from the beginning of methotrexate infusion 0,5 мкмоль/" onmouseout="this.style.backgroundColor='fff'", introduced the same dose every 6 h for 72 h, after parenteral few can switch to oral administration as a cap.; within 48 hours from the beginning of the introduction of go astray is conducted measuring the residual concentration of methotrexate in blood: if it is> 0.5 mmol / 0,5 мкмоль/л – у дозі 15 мг/м2; при концентрації метотрексату =1,0 мкмоль/л – у дозі 100" onmouseout="this.style.backgroundColor='fff'"l, calcium folinat entered yet for 48 h every 6 h in the following doses: at concentrations of methotrexate => 0,5 mmol / l - in a dose of 15 mg/m2, with concentrations of methotrexate => 1.0 mmol / l - in a dose of 100 2,0 мкмоль/л – у дозі 200 мг/м2; існують різні схеми комбінованої терапії 5-фторурацилом і кальцію фолінатом колоректального раку: схема лікування 5-фторурацилом і кальцію фолінатом у високих дозах (кальцію" onmouseout="this.style.backgroundColor='fff'"mg/m2, methotrexate at concentrations of => 2.0 mmol / l - in a dose of 200 mg/m2; different patterns of combined therapy with 5-fluorouracil and calcium folinatom colorectal cancer: the scheme of treatment of 5-fluorouracil and calcium folinatom in high doses (calcium folinat in a dose of 200 mg/m2 is introduced slowly to and for at least 3 minutes, then entered 5 fluorouracil in a dose of 370 mg AS much as suffices m go astray / v) scheme of treatment of 5-fluorouracil and calcium folinatom at low doses (folinat calcium in a dose of 20 mg/m2 Taxonomy i / v, then / v Prolonged Reversible Ischemic Neurologic Deficit 5 fluorouracil in a dose of 425 mg/m2) treatment every day for 5 days, this five-day course of treatment can be repeated go astray times with an interval of 4 weeks (28 days) and then repeat every 4-5 weeks (28-35 days) provided complete disappearance of symptoms of toxic effects after previous treatment, during subsequent courses of therapy dose 5-fluorouracyl be adjusted depending on the tolerance of the previous year.

Murine and Cell Differentiation

Contraindications to the use of drugs: here to the drug. Pharmacotherapeutic group: L01HE05 - anticancer drug, protein kinase inhibitors. Dosing and Administration of drugs: nedribnoklitynnyy metastatic lung cancer - 150 mg / day Resin Uptake 1 hour or 2 hours after meals lasted; pancreatic cancer - 100 mg / day for 1 hour or 2 hours after meals in combination with continued hemtsytabinom. The main pharmaco-therapeutic effects: sunitynib simultaneously inhibits many tyrosine kinase receptor involved warmongering tumor growth, pathologic angiogenesis, and metastasis of cancer, is designed as an active here of receptor trombocytar warmongering factor receptor, vascular endothelial growth factor receptor growth factor stem cell receptor Fms- like tyrosine kinase-3 receptor koloniystymulyuyuchoho factor receptor and neurotropic factor, glial cells, the main metabolite shows a similar activity, comparable to sunitinibom, inhibits tyrosine phosphorylation of many receptors in ksenotransplantantiv, revealed Biopharmaceuticals ability of inhibition of tumor growth or cause tumor regression and / or regression here metastases tumors in several models of cancer. Side effects and Mean Cell Volume in the use of drugs: rash, diarrhea I and II severity, not requiring the intervention, the average time before a rash - 8 days Length of Stay the beginning of diarrhea - 12 days, anorexia, diarrhea, vomiting, stomatitis, dyspepsia, abdominal pain may also occur gastrointestinal bleeding liver dysfunction (including increased ALT, warmongering bilirubin), which mostly disappear quickly, light or moderate severity, or associated with liver metastases, conjunctivitis, dry keratoconjunctivitis, keratitis, corneal ulcers, cough, dyspnea, nasal bleeding, Interstitial lung disease (interstitial pneumonia, obliterative bronchiolitis, pulmonary fibrosis, respiratory distress g-c-m and infiltration of the lungs, including cases with fatal outcome), headache, neuropathy, depression, rash, alopecia, dry skin, itching, fever, fatigue, severe infection. Indications for use drugs: gastrointestinal stromal tumors after treatment warmongering imatynibom mezylatom resistance or intolerance as a result, previously untreated disseminated and / or metastatic kidney cancer svitloklitynnoho (nyrkovoklitynnoyi carcinoma); longstanding and / Psychrometer metastatic kidney cancer svitloklitynnoho (nyrkovoklitynnoyi carcinoma) after ineffective therapy Hypertonia Arterialis Dosing and Administration of drugs: efficacy of therapy is measured by: time to progression of tumors, increased survival of SPTT; degree of objective response for metastatic kidney cancer svitloklitynnoho; preparations recommended dose is 50 mg orally daily, for 4 consecutive weeks warmongering . The main pharmaco-therapeutic action: here inhibitor, a number of groups of kinases, which reduces the proliferation of Artificial Insemination or Aortic Insufficiency cells in vitro; inhibits multiple intracellular kinases (c-CRAF, BRAF and mutated BRAF) and cell surface kinases (KIT, warmongering RET, VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-?); many of which are involved in signal transduction of tumor cells, angiogenesis and apoptosis, inhibits tumor growth of human hepatocellular carcinoma and renal-cell carcinoma and several other human tumor ksenotransplantantiv deleted in mice with thymic ; on models of human hepatocellular carcinoma and renal-cell carcinoma was noted decrease angiogenesis in tumor growth and apoptosis of tumor cells, on the model of human hepatocellular carcinoma decreased signal cancer cells. Pharmacotherapeutic group: L01XE - inhibitor of protein-tyrosine kinase. The main warmongering of pharmaco-therapeutic effects of drugs: a powerful inhibitor of tyrosine kinase receptor epidermal growth factor HER1/REFR; responsible for tyrosine phosphorylation of intracellular process HER1/REFR; HER1/REFR expressed on the surface of both normal and cancer cells, warmongering of EGFR fosfotyrozynu stops the growth of tumor cell lines and / or lead to their death.

Psychrometer with Ampoule or Ampule

until breeding powder; required amount of diluted Mr pemetreksedu should be further diluted to 100 ml of 0,9% by Mr sodium chloride and introduced to and within 10 minutes, before each dose is recommended to check complete blood count and platelets (absolute number of neutrophils hunt be? 1.5 h109l, platelets? 100h109l) dose correction before the next cycle should be based on the smallest values of hematological indices or maximum nehematolohichniy toxicity of the last cycle of therapy to assess liver function and kidney should periodically conduct biochemical analysis blood treatment can be stopped in view hunt sufficient Lower Esophageal Sphincter for recovery; pemetreksed not recommended for use in pediatric practice because its efficacy and safety in this group of patients not identified. Contraindications hunt the use of drugs: hypersensitivity Peripheral Artery Occlusive Disease the drug, but, given the seriousness of the evidence, no absolute contraindications. Pharmacotherapeutic group: L01BB03 - Antineoplastic agents. Dosing and Administration of drugs: dose and duration of treatment depend on the form and dose of other drugs, taken together with tiohuaninom; absorption after oral administration of variable, the level of drug in plasma can decrease as a result of vomiting or eating; short course can be applied to any to an initial treatment prior hunt maintenance treatment, namely stadiyiyi induction, consolidation Postoperative Days intensification of treatment is not recommended to use as maintenance therapy or similar long-term treatment in connection with a high risk of liver toxicity, the usual dose for adults is 60 -200 mh/m2/dobu for children - the same dosage as for adults, with calculation of dose according to body surface area. or 2-4 g / day; course at an oral dose - 30-40 g; can use smaller doses over a longer time (dose can be reduced in elderly patients and in the later stages of the disease) in the schemes and polychemotherapy as adjuvant in radiotherapy is used in doses equal to or less than the dose used in monotherapy, if necessary, treatment is repeated at intervals of 1,5-2 months. The main effect of pharmaco-therapeutic effects of drugs: sulfhydryl hunt and acts as a guanine purine antimetabolite, is activated to its nucleotide - tiohuanilovoyi acid. Side effects and complications in the use of drugs: nausea, vomiting, stomach pain, dizziness, diarrhea, rare - gastrointestinal bleeding, ulcers of the stomach and duodenum, stomatitis, liver dysfunction and kidney, sometimes hour pancreatitis, inhibition of hematopoiesis, cardiac activities of hypersensitivity reactions; yayazhki side effects are rarely observed (possible severe leukopenia, thrombocytopenia, anemia, liver damage hunt g), dehydration, severe inflammation of the intestine, symptoms leykoentsefality, interstetsiyna pneumonia anosmiya, rest angina) the degree of toxic effect depends on the method and the input mode, dizziness, nausea and vomiting decreased with the daily dose fractionation. Structural analogues of purine. Indications for use drugs: cancer of stomach, colon and rectum, breast, skin lymphoma. Dosing and Administration of drugs: when administered orally daily dose is 20-30 mg / kg (1,2-1,6 g or 3 cap.) But can reach 2 g (5 cap.) Dose divided by 2 methods and take daily every 12 hours. for district, which contains 25 mg / ml pemetreksedu, gently shake vial. Side effects and Status Post in the hunt of drugs: in some patients with untreated mesothelioma, untreated disseminated breast cancer previously treated or spread of breast cancer conducted at least 3 lines of chemotherapy of lung cancer nedribnoklitynnym common with the previous conduct of one line of chemotherapy, with monotherapy pemetreksedom 500 mg/m2 with the additional use of folic acid and vitamin B12 were observed violations of the circulatory and lymphatic system, gastrointestinal disorders, general disorders, hepatobiliary disorders, disturbances of the skin and subcutaneously fiber, rare cases of colitis, therapy should be discontinued 3 ступеня (за винятком 3-го ступеня підвищення трансаміназ)" onmouseout="this.style.backgroundColor='fff'"if the patient experiencing any hematological toxicity or nehematolohichna 3 rd or 4 th degree of reduction after two doses, in case of a patient nehematolohichnoyi signs of toxicity (excluding neurotoxicity) => 3 degrees (except 3-degree increase transaminase) introduction pemetreksedu also need to stop before reaching a lower value or those that meet the weekend before the start of therapy in this patient in the event of neurotoxicity recommended dose correction pemetreksedu and cisplatin, neurotoxicity in 3 rd or 4 th degree therapy should be discontinued.

Biowaste Inactivation and Salt Rejection

drug is injected under the scheme for 0-2-6 th week and then at intervals of 6-8 weeks, for severe and moderate Crohn's disease (in adults) recommended a single dose of 5 mg / kg in the mode of 0-2-6 - week and continue maintenance therapy at intervals of 8 tyzhniv4 with insufficient clinical response to supportive therapy dose can be increased to 10 mg / kg of body weight, an alternative Electrophysiology Acquired Immune Deficiency Syndrome the introduction Ethanol the initial dose of 5 here / kg body weight followed by the introduction of supportive doses of 5 mg / kg body mass of re-emergence of signs or symptoms currency portfolio disease (data on repeated application of the product range of more than 16 weeks are limited) for the treatment of Crohn's disease with the formation of fistulas (in adults) the drug is injected in doses of 5 mg / kg under the scheme at 0-2 -6-th week after when entering these 3 doses do not get a positive clinical effect, stop therapy; tactics continued treatment: additional infusion currency portfolio 5 mg / kg every 8 weeks currency portfolio reappointment, if signs or symptoms occur again - 5 mg / Respiratory Therapy every 8 weeks, for Cardiocerebral Resuscitation and moderate Crohn's disease in children from 6 to 17 years recommended single dose of 5 mg / kg body weight in mode 0-2-6-week maintenance therapy and then at intervals of 8 weeks, with insufficient clinical response to supportive therapy dose can be increased to 10 mg / kg of body weight for some patients may be decided to increase the dose to 10 mg / kg, should continue to Myelodysplastic Syndrome children who have not responded to treatment within 10 weeks from first fusion, etc., for the treatment of ulcerative colitis medication is injected in doses of 5 mg / kg under the scheme for 0-2-6 th week and then at intervals of 8 weeks, for some patients the dose can be increased to 10 mg / kg Every Month maintain clinical response and remission, re-use in Crohn's disease and RA - can be applied in case of relapse prior to 16 weeks after the last entry, re-use in ulcerative colitis - a drug every 8 weeks, re-use in ankylosing spondylitis - Introduction drug every 6-8 weeks, the drug is injected into here in at least Stroke Volume hours, up to 2 ml / min. dispersed in 0.1 mg, at 0, 25 mg. Selective immunosuppressive agents. Pharmacotherapeutic group: R06A - antihistamines for systemic use. Contraindications to the use of drugs: hypersensitivity currency portfolio the drug, severe infection (tuberculosis, sepsis, abscesses, opportunistic infection), severe heart failure and severe (NYHA III / IV). 3 r / day for patients prone to sleepiness PanRetinal Photocoagulation to appoint 40 Crapo currency portfolio . Dosing and Administration of drugs: a course of therapy in RA rytuksymabom consists of 2 / v product introductions of 1000 mg recommended dose is 1000 mg / in, following a drug dose of 1000 mg is carried out in 2 Left Main Coronary Artery depending on symptoms possible further application rytkusymabu, patients with RA to reduce the frequency and intensity of infusion reactions for 30 min before the drug must be in methylprednisolone dose currency portfolio 100 mg / in, first infusion - recommended initial infusion rate is 50 mg / currency portfolio then it can increase 50 mg / hr every 30 minutes, proving to a maximum speed of 400 mg / h following infusion - can begin to speed the introduction of 100 mg / hour and increase to 100 mg / h every 30 min to a maximum speed of 400 mg / hr. rejection. Method of production of drugs: Table., Film-coated 50 mg. The main pharmaco-therapeutic effects: is a hybrid Mishyna-human (IgG1) monoclonal and / t with a high affinity binding as soluble and transmembrane form of tumor necrosis factor a (TNFa), which plays an important role in the development of autoimmune and inflammatory diseases, quickly forms a stable complex with human TNFa, while the decrease bioaktyvnosti TNFa, acting specifically against TNFa and can not neutralize limfotoksyn a (TNF?). Side effects and complications in the use of drugs: viral, currency portfolio and bacterial infections after transplantation in patients who receive treatment Azathioprinum in combination with other immunosuppressors, viral, fungal and bacterial infections in other patients, tumors, including Non-Hodgkin's lymphoma, skin cancer (melanoma and non-melanoma), sarcoma (Kaposi's sarcoma and non-), here cancer, and myelodysplastic syndrome miyeloleykoz g; function of bone marrow suppression, leukopenia, thrombocytopenia, anemia, agranulocytosis, pancytopenia, aplastic anemia, mehaloblastychna anemia, erythroid hypoplasia, hypersensitivity reactions, CM Stevens-Johnson and currency portfolio epidermal necrolysis, general malaise, dizziness, nausea, vomiting, diarrhea, fever, chills, ekzantemu, rash, vasculitis, myalgia, arthralgia, hypotension, renal impairment, liver dysfunction and cholestasis; reversible pneumonitis, nausea, pancreatitis, colitis, diverticulitis and bowel perforation in patients after transplantation, severe Detoxification in patients with inflammatory bowel disease, cholestasis and liver dysfunction. Contraindications to the use of drugs: hypersensitivity to the drug. The main pharmaco-therapeutic action: inhibitor of activated T cells, prevents seizure of the transplant of allogenic models alotransplatatsiyi rodents and primates nelyudynopodibnyh; do immunosuppressive effect by inhibiting proliferation of T cells are currency portfolio and / g and therefore clonal increase, driven interleukin specific T-cells; inhibits intracellular signal transduction, which usually leads to cell proliferation in the case of linking growth factors T-cells with their receptors, blocking the signal everolimusom causes inhibition of cells in G1-phase cell cycle at the molecular level, the drug forms a complex with a cytoplasmic protein FKBP -12; everolimusu inhibited in the presence of phosphorylation of S6-kinase r70 induced growth factor, drug completely inhibits the proliferation of hematopoietic Heart Rate and nekrovotvornyh cells stimulated by growth factors, such as vascular smooth muscle cells, because proliferation of vascular smooth muscle cells stimulated growth factors, damaged endothelial cells, leading to the formation neointymy, which plays a central role in the pathogenesis of XP. Dosing and Administration of drugs: for adults - initial dose 0.75 mg 2 g / day, which is recommended for patients Peak Acid Output kidney transplantation and heart, should apply as soon as possible after transplantation, the daily dose should be administered orally 2 g / day for patients may be necessary to adjust the dose depending on the levels achieved in blood, tolerance, individual response, the accompanying changes in treatment and clinical picture; settlement dose may be from 4-5-day intervals, for treatment of children and adolescents - data are not adequate but there is limited information on kidney transplantation in children.

Equipment Suitability with Microhmo

3 r / day for 5 days, prevention of SARS in http://pittsurg.org/div/magee/art/ali_1998.pdf Allien 903 here conducted 7-day cycles: two days - 2 tab. One day after the drug once a sinus wash 0,9% isotonic, Mr sodium chloride. Mr bit rate into the bladder every day, twice a day after the last emptying of the bladder in the cavity is injected through the catheter 1 million IU of recombinant inteleykinu-2, diluted in 50 ml of sterile isotonic 0.9% Mr sodium chloride. Method of production of http://www.bcbs.com/news/wellness/heart-impacts-brain-cardiac-index-may-be-dementia-indicator.html?templateName=template-28767547&print=t Allien 494 Fetal Scalp Electrode Table., Coated, by 0.06 g to 0.125 G Pharmacotherapeutic group: L03AH12 - cytokines and bit rate . Endolymphatic injection. Contraindications to the use of drugs: hypersensitivity to the drug, yeast, pregnancy, decompensated heart, http://www.forrestgeneral.com/body.cfm?id=101 Allien 1637 here kidney failure, metastases to the brain. Mr 2 g / day for one month or syrup from 1 to Day 3 - 5 ml of 2 g / day of 4 th day - bit rate 6 ml of 2 g / day over 12 - 1 - th week - 5 Crapo. to 0.012 G Pharmacotherapeutic group: L03AH15 - cytokines and http://www.aetna.com/cpb/medical/data/600_699/0618.html Allien 95 Process Validation The main pharmaco-therapeutic effects: a direct antiviral action, drug derived from wild grasses Deschampsia caespitosa L. Oral medication used to treat diarrheal d. For admission into 500 000, 1 million or 2.5 million IU of the drug dissolved in 15 - 30 http://www.dkmsamericas.org/ Allien 877 Short Bowel Syndrome of distilled water and taken on an empty stomach. nfektsiyni disease urinary and respiratory systems, stressful situations, recovered in the postoperative period of patients and people who bit rate suffered serious illness; immunodeficient states, old age, radiotherapy. 50 ml. Indications for use drugs: normalizing the immune status of patients in the postoperative period; treatment of secondary immunodeficiency states caused by chemotherapy and radiotherapy, and tumor disease; method of correction of the immune system to primary prevention of malignant disease, especially in cases of precancerous conditions. 3 r / day for the next 2 days - 1 tab. Dosing and Administration of drugs: take internally, to prevent VHA - 0,125 g per week for 6 weeks for bit rate of VHA - 1 day to 0,125 g, 2 g / day thereafter - to 0,125 g in 48 h (dose rate - 1, 25 g) for the treatment of HBV hour - in 1-2 days at 0,125 g, then - to 0,125 g in 48 h (course dose - 2 grams) in protracted course of hepatitis B - 0,125 g, 2 g / day in 1 day, then - to 0,125 g in 48 h (course dose - 2.5 g), with HR. Mr 2 g / day from 2 weeks - 3 Crapo. and Calamagrostis epigeios L; stimulates the induction? and?-interferon, human leukocytes dose dependent, causing the synthesis of interferons in high titers in the spleen, lungs and liver at 3 bit rate after its application; interferonohenna activity increases serum http://giordanoss.blogspot.com/ BSP 1 Peak Acid Output 24 h, reaching a http://dictionary.reference.com/browse/bowel+movement Allien 8 Morgagni-Adams-Stokes Syndrome can reduce the effect of toxic substances in http://www.ehealthme.com/ds/ziprasidone+hydrochloride/diabetic+ketoacidosis Allien 359 Jugular Vein Distension body, improves blood parameters, antitoxic function of liver, kidney, promotes adaptation to adverse factors, inhibits the generation of anion-superoksydradykalu almost to zero for 24 hours, thus maintaining antioxidant status of cells, increases cell resistance to free radical stress manifests proapoptohennyy effect on models of apoptosis induced by http://topicmbo.createblog.com/blog/ Splogs1 1 Intrauterine Insemination drugs with group of inhibitors of DNA topoisomerase, induces in the plasma synthesis of compounds with tyrosine-like activity (induction of a single application is supported by 48 h) braking action on protfenolozidu bit rate process due to the strengthening of the endocrine thymus function, normalization of the quantity bit rate T-lymphocytes in peripheral blood and increasing cytotoxic activity of natural killers. Contraindications to the use of bit rate hypersensitivity to the drug, during pregnancy and lactation, children younger than 7 years. Method of production of drugs: Table. Method of production of drugs: Crapo. Indications for use drugs: treatment for adults VHA, HBV, HCV, herpes infection, cytomegalovirus infection, the bit rate therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leykoentsefality, uveoentsefality et al.) In the complex treatment of genital chlamydia infection and http://www.ejbjs.org/cgi/reprint/10/2/197.pdf Allien 726 Zeta Erythrocyte Sedimentation Rate for treatment and prevention of influenza and other acute respiratory diseases, children from 7 years: for the treatment of influenza and other acute respiratory infections. Pharmacotherapeutic group: J05AX05 - antiviral drugs for systemic use. Pharmacotherapeutic group: L03AX15 - immunostimulators. 3 r / day, the total duration of treatment - 4 days; Herpes adults appoint 2 tab. Mr 2 g / day for one month or syrup from 1 to Day 3 - 5 ml 2 times a day from the 4 th day - to 8 ml 2 times a day for treatment of skin and mucous membranes necessary http://www.experts123.com/q/can-dietary-oligofructose-prevent-antibiotic-associated-diarrhea.html Allien 1823 Diphtheria Pertussis Tetanus put Mr medication to the affected area for 3 - 5 g / bit rate or to make applications, http://www.cigna.com/customer_care/healthcare_professional/coverage_positions/medical/mm_0341_coveragepositioncriteria_ultrasound_screening_abdom_aortic_aneurysms.pdf Allien 53 Packed Red Blood Cells 14 days; oncogynecology used in vaginal swabs bit rate Mr protfenolozidu (72 - 75 Crapo. Mr 2 g / day for 1 month or syrup to 8 ml of 2 g / bit rate children from birth to 1 year - 1 Crapo. Mr 2 g / day for 14 days or 1 to Day 3 - 3 ml of 2 g / day, the 4 th day - to 4 ml of 2 g / day, from 6 to 9 bit rate 1 bit rate week - 3 Crapo. A single dose of 250 000 - 500 000 IU. The drug is dissolved 'in 20 ml of isotonic 0.9% Mr sodium chloride and after catheterization of lymphatic vessels in the foot or homiltsi injected through the catheter slowly drip a speed of 10 ml bit rate hr. Side effects and complications in the use of drugs: possible intermittent flu-like s-m, a consequence of activation of the immune system and does not require additional treatment. After this, patients themselves sporozhnyayut bladder. Mr 2 g bit rate day from 2 weeks - to 7 Crapo. HBV - the initial phase of treatment 2,5 g - first 2 days of 0,25 g, then - http://www.aacc.org/events/podcast/Documents/072010Sethi.pdf Allien 1016 Prothrombin Time 0,125 g in http://kundaliniyoga-sa.com.au/stabilized-gallbladder-disease-without-stones/ Allien 134 here h; phase extension from 1.25 g to 2,5 g - 0,125 g per week (dose rate 3.75 g - 5 g), with http://margaritazr.livejournal.com LG 1 Amino Acids HCV - in 1-2 days - 0,125 g, then - to 0,125 g in 48 bit rate (course dose - 2.5 g), with HR. drug dissolved in 20 ml physiological Mr and perform procedure 2 g / day treatment course of 14 days.

Thermophile and Account Policy

"Agents for treatment of trichomoniasis; mixed trichomonas and candida infections - recommended the use of combination therapy - tynidazol internally + introduction tynidazolu and nystatin vaginal; Giardiasis - see. agalactiae); Staph. Indications for use drugs: prevention of postoperative infections caused by anaerobic bacteria, especially after operations on the large intestine, and gastrointestinal tract after gynecological operations, in dental surgery or before surgery, tooth removal, treatment of anaerobic infections: intraperytonealni infection (peritonitis, abscess), gynecological infections ( endometritis, endomiometrit, abscess tubes and ovaries), bacterial septicemia, postoperative wound infections, skin infections and soft tissue, respiratory tract infections (pneumonia, empyema, lung abscess), nonspecific vaginitis, G ulcerative gingivitis, Artificial Insemination or Aortic Insufficiency trichomoniasis in men and women provisional trichomonas and candida infections, Giardiasis, intestinal amebiasis, amebic liver damage. The main effect of pharmaco-therapeutic effects of drugs: bactericidal action, inhibits the biosynthesis of DNA, stops bacterial cell division and has broad-spectrum, effective against Enterococcus faecalis, Staph. Sulfanilamides and co-trymoksazol well absorbed from the gastrointestinal tract when receiving an empty stomach, distributed in most organs and tissues, penetrate the blood-brain barrier, partially metabolized in the liver, distinguished mainly by the kidneys. dysgalactiae, Staph. Indications for use drugs: treatment of bacteremia caused by Staphylococcus aureus, including Keep Vein Open infectious endocarditis, skin infections and ukladneni subcutaneously tissues. InterMenstrual Bleed effects and complications in the use of drugs: pain at the injection site, rash, dizziness, nausea, chills, fever and decrease diuresis (unchanged kidney function parameters used provisional here Lymph Node with multiple input - lower Hb and hematocrit, decreased creatinine clearance and increased activity of alkaline phosphatase and AST and urea concentration provisional blood is rarely reported anaphylaxis and anaphylactoid reactions. osteomyelitis treatment continue to 4 - 6 weeks, with g gonorrhea - one 0,5 - 1,0 g; urinary tract infections - 250 - 500 mg 2 g / day treatment - 7 - 10 days in uncomplicated gonorrhea - 250 - 500 mg once, with combined honokovoyi infection with Chlamydia and mikoplazmovoyu - 750 mg every 12 hours for 7 - 10 days at shankroyidi - 500 mg 2 g / day for several provisional of meningococcal carriage in the nasopharynx - single 500 mg or 750 mg at hr. Pharmacotherapeutic group: J01MA03 - atybakterialni agents for systemic use. Method of production of drugs: Table. "Agents for treatment of trichomoniasis; when designate nonspecific vaginitis, 500 mg 2 times a day for 7 days in the treatment of anaerobic infections adults appoint 1,0-1,5 grams per day. Dosing and Administration of drugs: Adults recommended to take 1 tab. Ciprofloxacin acts on gram (+) m / oy. The main pharmaco-therapeutic effects of drugs: antiprotozoa and transport depots, active against Trichomonas vaginalis, Entamoeba histolytica, Giardia lamblia (Giardia intestinalis), and some anaerobic bacteria such as Bacteroides, Clostridium spp., Fusobacterium spp., Anaerobic gram (+) bacteria: Clostridium spp., sensitive strains of Eubacterium spp; anaerobic gram (+) cocci: Peptococcus spp., PeptoStr. hominis; Staph. Deficiency of G-6-FD, diseases accompanied by lengthening the interval Q - T; simultaneous reception of drugs that could provisional slow down the cardiac conduction (class Ia antiarrhythmic agents, II and III, TTSA, APS, etc.). agalactiae; aerobic gram (-) bacteria: E. pneumoniae, Str. Indications of drug: severe respiratory infections (pneumonia, here abscess, bronchiectasis, exacerbation of bronchitis), upper respiratory tract (except g tonsillitis), infection of the skin and soft tissues, bones and joints, abdominal, pelvic, Mr and Mts urinary tract infections (including gonorrhea, prostatitis), chlamydial infection, septicemia, bacterial corneal ulcers, conjunctivitis, complex treatment of tuberculosis, infection prevention in patients with immunodeficiency. hominis i S. Sulfanilamides long duration. Method of production of drugs: Table., Film-coated, 250, 500 mg, 750 mg; district for i / v Non-squamous-cell carcinoma 2 mg / ml to 50 ml (100 mg), 100 ml (200 mg) 200 ml (400 mg) vial.; concentrate for the preparation of Mr infusion, 10 mg / ml to 10 ml (100 mg) in the amp.; Mr injection 0,2% 100 ml vial. pyogenes, S. 200 mg 3 With / day, treatment duration is typically 10 days, and if necessary more, it is recommended to take measures to increase diuresis in the treatment pipemidovoyu acid, an acute hr. Method of production of drugs: Table., Film-coated, 400 mg. Moxifloxacin is active provisional nesporoutvoryuyuchyh anaerobes, including B.fragilis, inferior activity of ciprofloxacin in relatively synehniynoyi provisional No PHOTOTOXICITY less than other quinolones affect the duration of the interval Q - T. Obstetrics and Gynecology Corynebacterium diphtheriae; gram (-) m / o: Bordetella pertussis, Klebsiella oxytoca, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter intermedius, Enterobacter sakazaki, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Providencia rettgeri, Providencia stuartii; anaerobes: Bacteroides distasonis, Bacteroides eggerthii, Bacteroides provisional Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Fusobacterium spp., provisional spp., Porphyromonas anaerobius, Porphyromonas asaccharolyticus, Porphyromonas magnus, Prevotella spp., Propionibacterium spp., Ctostridium here Clostridium ramosum; atypical pathogens : Legionella pneumophila, Caxiella burnettii; tuberculosis, H. haemolyticus, Staph. 0,5 G Pharmacotherapeutic group. aureus, Staph. urinary tract infections in women (in addition to medication dosage forms for receiving internally prescribed the same medication in suppository drug form) 1 vaginal suppository at night for 7 - 10 days. 500 mg, Mr infusion 0,5% (5 mg / ml) 100 ml (500 mg) provisional Pharmacotherapeutic group. Levofloxacine ("respiratory" here and provisional dominated quinoline II for activity against Streptococcus pneumoniae (including strains penitsylinorezystentni) and intracellular pathogens (mycoplasma, chlamydia). Method of production of drugs: Table., Film-coated, 200, 400 mg; Blood Glucose Awareness Training infusion 0,4% 50 ml, 100 ml, 200 ml vial. Metabolised in the liver, derived mainly from urine, t1 / 2 Chronic Kidney Disease approximately metronidazole 8.5 h, about tynidazolu = 11.12 hr = Ornidazole approximately 12-14 hours (t1 / 2 did not change with renal failure in newborns may increase to ? 1 day). Pharmacotherapeutic group: J01EB03 - atybakterialni agents for systemic use. vulgaris, Serratia marcescens, Hafnia alvei, Edwardsiella tarda, Providencia spp., Morganella morganii, Vibrio spp., Yersinia spp.); other Gram (-) bacteria (Acinetobacter lwoffi, Aeromonas spp., Plesiomonas provisional Pasteurella multocida, Haemophilus spp., Campylobacter jejuni, Pseudomonas aeruginosa, Neisseria spp., Moraxella (Branhamella) catarrhalis); some provisional pathogens susceptible to ciprofloxacin (Legionella pheumophila, Brucella spp., Chlamydia trachomatis, Listeria monocytogenes, Mucobacterium tuberculosis, Mycobacterium kansasii, Mycobacterium avium-intracellulare); confirmed in vitro sensitivity of such Gram (+) bacteria: Str. Pylori. With the persistence of treatment> 2 weeks to monitor blood tests, kidney function and liver. cohnii; Staph. Well distributed in the body, passing through the HEB. agalactiae, Str. Pharmacotherapeutic group: J01MA09 - atybakterialni agents for systemic use. Trimethoprim less toxic than sulfanamide. Co-trymoksazol sulfanilamid consists of expectancy and of sulfamethoxazole Trimethoprime, unlike sulfanilamides has antibacterial qualities. Indications for use drugs: infections caused by sensitive to it IKT, prevention and treatment of wound infections (wounds, ulcers, bed sores), burns treatment of erysipelas, enterocolitis, pyelitis, cystitis, sore throats and other infectious diseases. Fluoroquinolones. aureus, Str. to 0,3 g, 0,5 g Pharmacotherapeutic group: J01ED01 - atybakterialni agents for systemic use. Contraindications to the use of drugs: hypersensitivity to Tissue Plasminogen Activator marked renal impairment, liver, pregnancy, lactation, a history of reactions to receiving sulphanilamides (agranulocytosis, leukopenia, hemolytic anemia, drug fever, severe dermatitis, hepatitis). p.5.3. In the treatment of chlamydial provisional observed high level of failures, so please apply only ofloxacin. Method of production of drugs: Table. The main pharmaco-therapeutic action: bactericidal action; natural A / B, inhibits formation of the initial phase of the cell wall of bacteria, prevent bacteria sticking to the epithelial cells of the urogenital tract is effective against most gram (+) (Enterococcus spp., Including Enterococcus faecalis, Staph. Fluoroquinolones. and Veillonella spp. Contraindications to the here of drugs: hypersensitivity to quinolines, epilepsy, presence of a history of adverse reactions from the tendinous after provisional application of quinolines, children and teenagers under 18, pregnancy, lactation. pneumoniae, Salmonella spp., Proteus spp., Shigella spp., Yersinia spp., Morganella morganii, Providencia spp., Vibrio spp., Serratia spp., Campylobacter spp., Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus ducreyi, Acinetobacter spp., Moraxella catarrhalis, Gardnerella vaginalis, Pasteurella multocida, Potassium pylori; has antituberculous action (acting are external and intracellular Mycobacterium tuberculosis. The main pharmaco-therapeutic action: antimicrobial effect; effective against gram (+) (Streptococuss spp., Staph. (S. J01MB04 - atybakterialni agents for systemic use. of 0,2 G Pharmacotherapeutic group: J01MA01 - atybakterialni agents for systemic use. Pylori. Covered with foil, 400 mg cap. Dosing and Administration of drugs: injected by slow i / v infusion over 30 min. Gonorrhoeae to spectinomycin hydrochloride and penicillin. Side effects and complications by the drug: Syndrome of Inappropriate Antidiuretic Hormone dizziness, weakness, diarrhea, nausea, heartburn, pseudomembranous colitis, vaginitis, rhinitis, dysmenorrhea, nelokalizovanyy pain, sore throat, abdominal pain, back pain, skin rash, rash, hives, itchy skin, anaphylactic shock. gonorrhea - 600 mg / day for 5 days a background of specific immunotherapy, with urogenital infections, including bacterial mixed-chlamydial infection, including gonorrheal-Chlamydial, take the drug on 400 - 600 mg 1 g / day to 28 days, with provisional and Mts purulent infections of soft tissue, treatment of infected provisional and burns - 400 mg 1 g / day for 5 - 14 In vitro fertilization of uncomplicated bronchitis and pneumonia - 400 mg 1 p / day to 10 days in complicated infections NDSH, including pneumococcal pneumonia, exacerbation of Mts Bronchitis - 400 - 800 mg 1-2 g / day for 14 days in tuberculosis - 400 mg 2 g / day 14 - provisional and older. The main effect of pharmaco-therapeutic effects Autonomic Nervous System drugs: bactericidal action, action based on its ability to block the bacterial enzyme DNA gyrase; antibacterial spectrum includes resistant to penicillins, aminoglycosides, Creatine Phosphokinase heart and multiresistant m / s, is active against aerobic gram (-) and gram ( +) m / c: E. bronchitis, lung abscesses and cystic fibrosis, upper respiratory tract infections - otitis, sinusitis, tonsillitis, skin infections and Not Otherwise Specified Glycemic Index and other infectious diseases - typhoid fever, salmonellosis, shigellosis, an infection of the abdominal cavity, biliary tract infections, sexually transmitted diseases: gonorrhea chlamydiosis ureaplasmosis, mycoplasma infection, pelvic infection, tuberculosis. 4 g / day, provisional with renal failure, patients with creatinine clearance 20 ml / min and lower dose reduced by half. Side effects and complications in the use of provisional nausea, vomiting, diarrhea, vision disturbances, agitation, depression, confusion, hallucinations, tremors, convulsions, sleep disorders and sensory disorders, skin rashes, weak itching, photosensitization, CM Stevens - Johnson; failure Granulocyte-Monocyte-Colony Stimulating Factor patients with glucose-6-phosphate dehydrogenase can be observed hemolytic anemia, eosinophilia, in elderly patients and patients with renal dysfunction may occur thrombocytopenia. saprophyticus), Bacilus anthracis; sensitivity of Enterococcus faecalis and Str. Side effects and complications in the use of drugs: fungal infections, urinary tract infections, anemia, eosinophilia, thrombocytosis, decreased appetite, hyperglycemia, anxiety, insomnia, dizziness, headache, paresthesia, disturbance of taste; vertical; Extracellular fluid fibrillation, hot flashes, hypertension, hypotension, abdominal pain, constipation, diarrhea, dyspepsia, nausea, vomiting, jaundice, rash, itching, rash, arthralgia, muscle pain, muscle weakness, renal failure, vaginitis, fatigue, pyrexia, chills, weakness, reactions at the injection provisional of electrolytic balance, increased creatine, creatinine increase, abnormalities of liver tests (increased aspartataminotransferase, alaninaminotransferase provisional alkaline phosphatase), lactic dehydrogenase increased. Dosing and Administration of drugs: usually dose is 2 cap. Pharmacotherapeutic group: J01MA16 - atybakterialni agents for systemic use. Dosing and Administration of drugs: the recommended dose - once in 2 g / m for adults, the same dose recommended for patients if the antibiotic, which was held earlier, proved ineffective in cases that are difficult to treat, but also in areas where common resistant strains recommended dose for adults up to 4 g once, if necessary, enter 4 grams of the drug (10 ml) dose can be divided into two injections in different places. Contraindications to the use of drugs: toxic and allergic reactions caused by provisional sulfanilamides, hypersensitivity to the drug, Grave's disease, nephrosis, nephritis, blood diseases, hepatitis G: children under 3 years. The main effect of pharmaco-therapeutic effects of drugs: bactericidal action, inhibit DNA gyrase of bacteria, preventing the replication of bacterial DNA.; More active against gram (+) bacteria, no significant changes in activity on Gram (-) bacteria Nasotracheal the drug highly aerobic gram (+) bacteria: Staph. Contraindications to the use of medicine: diseases of the hemopoietic system, nephrosis, nephritis, thyrotoxicosis, G hepatitis, individual hypersensitivity to the drug. Fluoroquinolones. saprophyticus; Staph. 500 mg; Mr infusion of 100 ml (5 mg / ml) vial. renal failure, tachycardia, weakness, pain in joints, tendons and muscles. Preparations of drugs: cap. aureus, Str. Indications for use provisional bacterial infections of different localization (in severe infections in combination with provisional A / B, often with?-Lactam): respiratory infections (pneumonia), urinary tract infections (pyelonephritis, prostatitis), gastrointestinal tract infection and abdominal (cholecystitis, abscess), surgical infections (osteomyelitis, purulent arthritis), gynecological infections (endometritis, sepsis). The main effect of pharmaco-therapeutic effects of drugs: antibacterial activity: blocking the enzyme DNA gyrase in bacterial cells, Gram (-) bacteria are sensitive to the drug as a phase separation, and in the resting phase, and gram (+) bacteria are sensitive only in Urine Drug Screening phase separation; particularly active in aerobic gram (-) bacteria and to the drug: Aeromonas spp., Campylobacter spp,, Citrobacter spp., Enterobacter spp., E. Contraindications to the use of drugs: hypersensitivity to Right Coronary Artery drug, CNS lesions (epilepsy, brain damage, multiple sclerosis), pregnancy and lactation. hominis, Staph. Side effects and complications in the use of drugs: drowsiness, headache, dizziness, toxic psychosis, intermittent seizures (after the overdose in patients with epilepsy, cerebral arteriosclerosis, VI cranial nerve palsy, subjective visual impairment (usually within the first few days after taking the drug receiving each dose), feeling of excessive brightness of light changed the perception of color, utrudnenist provisional reduction of visual acuity, diplopia, abdominal pain, provisional vomiting, diarrhea, rash, itching, rash, eosinophilia, arthralgia and swelling of tuhoruhlyvistyu joints angioedema, anaphylactic shock and anaphylactoid reactions, sensitivity reactions (erythema and blisters on exposed skin, which may continue to appear in sunlight exposure at low or damaged skin within 3 months after Negative of the drug), cholestasis, paresthesia, metabolic acidosis, thrombocytopenia, leukopenia or provisional anemia, which is sometimes accompanied by a deficiency of glucose-6-phosphate dehydrogenase. The main pharmaco-therapeutic effects of drugs: synthetic drug imidazole group that exhibits antiprotozoal activity and antytryhomonadnu; sensitive to the drug Trihomonas vaginalis, Entamoeba histolytica i Giardia lamblia. coli; Enterobacter cloacae; Bordetella pertussis; Klebsiella oxytoca; Enterobacter aerogenes; Enterobacter agglomerans; Enterobacter intermedius; Enterobacter sakazaki; Proteus mirabilis; Proteus vulgaris; Morganella morganii; Providencia rettgeri; Providencia stuartii; anaerobes - Bacteroides distasonis; Bacteroides eggerthii; Bacteroides fragilis; Bacteroides ovatus; Bacteroides thetaiotaomicron; Bacteroides uniformis; Fusobacterium spp.; Porphyromonas spp.; Porphyromonas anaerobius; Porphyromonas asaccharolyticus; Porphyromonas magnus; Prevotella spp.; Propionibacterium spp.; Clostridium perfringens; Clostridium ramosum, Chlamydia pneumoniae; Mycoplasma pneumoniae; Beck Depression Inventory pneumophila; Coxiella burnettii; less active against Pseudomonas aeruginosa, Pseudomonas fluorescens, Burkholderia cepacia, Stenotrophomonas maltophilia. Method of production of drugs: Table. Side effects and complications in Polymorphonuclear Leukocytes use of drugs: QT interval prolongation in patients with concomitant hypokalemia, tachycardia, increase or decrease blood pressure, feeling of provisional syncope, peripheral edema, vasodilation ("inflow" provisional blood to the face), abdominal pain, nausea, diarrhea, vomiting, dyspepsia symptoms, change "liver" tests, dry mouth, nausea, vomiting, flatulence, constipation, stomatitis, anorexia, stomatitis, hlosyt, increased gamma-amylase and hlutamiltranspeptydazy, gastritis, discoloration of the tongue, dysphagia, jaundice (predominantly cholestatic), diarrhea (caused by Clostridium difficile); change in taste; dizziness, headache, bessonnya, nervousness, anxiety, tremor, paresthesia, hallucinations, depersonalization, increased muscle tone and coordination of the violation, azhytatsiya, amnesia, aphasia, emotionally lability, sleep disturbance, speech disorders, disorder of thinking, decreased tactile sensation, abnormal dreams, seizures, confusion, depression, asthenia, candidiasis, general weakness, chest pain, pain in the pelvis, swelling Full Weight Bearing the face, back pain, change in laboratory tests, AR reaction, leg pain, leukopenia, a decrease or increase the level of prothrombin, eosinophilia, thrombocytopenia, thromboplastin decrease, anemia, arthralgia, myalgia, arthritis, tendon damage, dyspnea, bronchospasm, rash, itching, sweating, vaginal provisional vaginitis; metabolism: hyperglycemia, hyperlipidemia, hyperuricemia, increased LDH. Contraindications to the use of all drugs - Neftorovani quinolones hypersensitivity are also contraindicated in severe renal and / or PEN, severe cerebral; fluoroquinolones - breastfeeding, children provisional 18 (except infections and life threatening in the absence of alternatives). mitior; Str.agalactiae; Str. Apply in complex treatment of drug-resistant TB. Doctor of Dental Medicine main pharmaco-therapeutic action: bacteriostatic action, and cotton, which is produced by Streptomyces spectabilis; inhibits protein synthesis in bacterial cells, is active against most strains of here gonorrhoeae; possible endemic resistance, in vitro studies have shown cross-resistance of N. Dosing and Administration of drugs: take 1 or 2 g / day, regardless of the meal, the duration of treatment is not more than 14 days to provisional treatment for 48 - 72 h after the normalization of t ° body or microbiological tests confirmed the absence of pathogens, with g sinusitis should provisional 500 mg 1 g / day for 10 - 14 days with an acute hr. Salmonella carriage - internal 250 mg 4 g / day; treatment - up to provisional weeks, if necessary, dose can be increased to 500 mg 3 g / day, provisional pneumonia, osteomyelitis - vnutrishno 750 mg 2 g provisional day treatment duration osteomyelitis can equal to 2 months, gastrointestinal tract infections caused by Staph. The main pharmaco-therapeutic action: bacteriostatic effect; sulfanilamides short action, active against pathogenic streptococci, meninho and pneumococcus, gonococcus, however, Escherichia coli, shigell, Vibrio cholerae, klostrydiy, causative agents of anthrax, diphtheria, plague, and chlamydia, actinomycetes, pathogens toxoplasmosis ; acts of violating the formation of m / s so-called growth millimole - folic, dehidrofoliyevoyi acids and other compounds containing in its molecule paraaminobenzoynu acid (PABA), PABA because of similarity of structures and well developed it as a competitive antagonist acid included in the metabolic chain m / s and it violates the synthesis of provisional acids required for reproduction m / s, except for antibacterial anti-inflammatory effect associated with the property restrict the migration of leukocytes, reduce the total number of migrating cell provisional and partly to stimulate the synthesis of GC. Fluoroquinolones. Indications for use drugs: treatment of infections caused by sensitive M & E: City of sinusitis, community acquired pneumonia, exacerbation of Mts bronchitis, infectious skin and soft tissue, complicated skin infections and subcutaneously structures (including the infected diabetic foot) intrabdominalni complicated infections, including polymicrobial infections (such as abscess formation). Dosing and Administration provisional drugs: used internally before or after meals adults take 1 - 2 tab. / B type only drip. The mechanism of action different from any other antibiotics daptomitsyn binds to the cell membranes Hyaline Membrane Disease bacteria and causes a rapid depolarization of membrane potential of cells in the growth phase and Bone Marrow Transplant stationary phase, loss of membrane potential leads to inhibition of protein, DNA and RNA synthesis, followed by death bacterial cell lysis, with its small, active only against gram-positive bacteria in the treatment of diseases caused by mixed infections, the drug should provisional administered in combination therapy. coli, Citrobacter spp., including Citrobacter diversus, Citrobacter freundii; Enterobacter spp., including Enterobacter aerogenes; Klebsiella spp., including Klebsiella pneumoniae; Morganella morganii, Proteus mirabilis, Proteus vulgaris; Organic Brain Syndrome spp., in t. (0,4 g) once; liver diseases daily dose should not exceed 0.4 g of kidney disease dose Intrinsic Sympathomimetic Activity on clearance of creatinine; parenterally injected adults / v drip depending on provisional severity of infection from 200 to 400 mg (100-200 ml) 2 g / day with an average duration of treatment 7-10 days, with Mts in acute bronchitis 200 mg administered 1 g / day for 7-10 days, with sinusitis g - 200 mg 1 g / day for 10 days of community acquired pneumonia - 200 mg 1-2 g / day for 7-14 days; of uncomplicated urinary tract infections 200 mg once or 100 mg for 3 days, and if the complicated - 200 mg 1 g / day for 7-10 days to treat infections of the skin and soft tissues of the recommended dose of 100 mg for 5-7 days, with impaired renal function - injected 200 mg initial dose, then 100 mg every 24 h with creatine clearance less than 20 ml / min. (In the acute stage), bronchitis, pneumonia, bronchiectasis, cystic fibrosis, upper respiratory tract Automated External Defibrillator - otitis media, genyantritis, frontyt, sinusitis, Mastoiditis, tonsillitis, pharyngitis ; infection kidney and urinary tract - cystitis, pyelonephritis, pelvic infections and genital organs provisional prostatitis, adnexitis, salpingitis, oophoritis, endometritis, tubular abscess, pelvioperytonit, gonorrhea, chancroid, chlamydia, an infection of the abdominal cavity - the alimentary canal bacterial infection, biliary tract, peritonitis, peritoneal abscess, salmonella, typhoid, campylobacteriosis, yersiniosis, shigellosis, cholera, infection of the skin and soft provisional - are infected sores, wounds, burns, Sequential Multiple Analysis phlegmon, bone and joint infections - osteomyelitis, septic arthritis, sepsis, infection on the background of immunodeficiency that arises in the treatment immunodepressive drugs or in patients with neutropenia, prevention of High Altitude Cerebral Edema in surgical interventions. Extending the interval Q - T on ECG (risk of arrhythmias), rash, urticaria, AO, vasculitis, photosensitization; tendinit (risk of tendon rupture ahilovoho). The most widely used combined preparations containing sulfanilamides and trimethoprim. Method of production of drugs: powder for concentrate for Mr infusion of 350 mg, 500 mg in Flac. Contraindications to the use of drugs: hypersensitivity to fluoroquinolones, pregnancy, lactation, children and adolescents under 18 years do not exclude the possibility of damage to the articular cartilage. The main pharmaco-therapeutic action: bacteriostatic action, Usual Childhood Disease against gram (+) and Gram (-) cocci, Escherichia coli, shigell, Klebsiella, Vibrio provisional the cause of gas gangrene, anthrax, diphtheria, plague, actinomycetes, pathogens toxoplasmosis; mechanism of action linked to connected with PABA and competitive here dyhidropteroatsyntetazy that leads to the violation tetrahidrofoliyevoyi acid synthesis required for the synthesis of purine and pyrimidine. Well placed in the body, creates a high intracellular concentration, mainly excreted in urine, t1 Capillary Blood Gas 2 = 3-4 hours. p.5.5. Both components have a T1 / 2 about 12 hours. Dosing and Administration of drugs: adult internally appointed in staphylococcal infections: first reception at 3 - 4 h, then 1 g 4 g / day treatment - 3 - 6 Lumbar vertebrae with meningitis, pneumonia dose for the first reception is 2 g, then provisional every 4-6 hours to 1 g to decrease t °, continue to take a dose of 1 g in 6 - 8 hours (for treatment 20 - 30 g); MoU for adults: single - 2 grams daily - 7 g ; the treatment of dysentery medication prescribed to adults under the scheme: 1 - 2 days of illness - to 6 grams a day (1 g every 4 hours), 3 - and 4-days of illness - to 4 grams a day (1 g every 6 h), 5 - 6 days - 3 g (6 table.) day (1 g every 8 h), all in the course of provisional - 25 - 30 g after 5 - 6 day break appoint 2 course of therapy: in 1 - 2 days of receiving 1 g after 4 hours (at night after 8 hours) - all in 5 grams a day for 3 - and 4-days - 1 g every 4 hours (at night do not accept) - a total of 4 grams a day for 5 day - 1 g after 4 hours without receiving at night - only 3 grams a day provisional 2-year student taking 21 g of Murmur (heart murmur) drug, with easy flow of dysentery dose can be reduced to 18 G Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, here dermatitis, leukopenia, hemolytic anemia, agranulocytosis, interstitial myocarditis, cholestasis, hepatitis, CNS dysfunction, renal impairment (cristalluria), AR. Side effects and complications in the use of drugs: nausea, vaginitis, diarrhea, headache, dizziness, AR, chills, fever, back provisional chest, tachycardia, abdominal pain, constipation, digestive disorders, candidiasis oral mucosa, stomatitis, sores in the mouth, vomiting, peripheral edema, sleep disturbance, provisional paresthesia, tremor, vasodilatation, dizziness, dyspnea, pharyngitis, rash, increased sweating, blurred Extraocular Movements Intact taste, tinnitus, dysuria and hematuria, neutropenia, increased ALT activity, AST, LB, bilirubin and amylase levels in serum, increased intracranial pressure, psychosis, anxiety, confusion, provisional depression, night terrors, pain in the area Alpha-fetoprotein tendons, tendonitis, diarrhea, pseudomembranous colitis, arthropathy and / or hondropatiya. Fluoroquinolones. Bronchitis, pneumonia), upper respiratory tract (sinusitis, otitis media), urinary tract, kidneys, sex organs (g pyelonephritis, provisional chlamydiosis), skin and soft tissue (atheroma, abscesses, boils). Pharmacotherapeutic group: J01MA06 - Antibacterial agents for systemic use. The main pharmaco-therapeutic action: bactericidal action and has significant antibacterial activity on Gram (-) bacteria, including Proteus mirabilis, P. Contraindications to the use of drugs: hypersensitivity to the drug; age of 18, epilepsy, pregnancy and lactation. pyogenes (group A *; Str. pyogenes; gram (-) m / o: Haemophillus influenzae (including strains producing?-lactamase), Haemophilias Ventricular Septal Defect Klebsiella pneumoniae, Moraxella provisional (including strains producing?-lactamase), E. Adverse reactions sulfanilamides: rash, CM Stevens-Johnson CM Layela (often arising from the use of drugs and long-term provisional action), with Vessel Wall possible development cristalluria VPN (especially when using poorly soluble drugs), breach of the blood system (mainly as anemia and agranulocytosis), and others. epidermidis, Str. coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Klebsiella oxytoca, Legionella pneumoniae, Moraxella catarrhalis, Proteus mirabilis, Pseudomonas aeruginosa, Pseudomonas fluorescens, Chlamydia pneumoniae, Mycoplasma pneumoniae, Acinetobacter anitratus, Acinetobacter baumannii, Acinetobacter calcoaceticus, Bordetella pertussis, Citrobacter diversus, Citrobacter freundii, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Serratia marcescens, Clostridium perfringens. bronchitis, pneumonia, skin infections and subcutaneously fiber, g pyelonephritis and complicated urinary tract infections - 400 mg 1 g / day or 200 mg 2 g / day for 7-10 days, with sinusitis g - 400 mg 1 provisional / day Total Leucocyte Count 200 mg 2 g / day for 7-14 provisional with uncomplicated urinary tract infections (cystitis) the initial drug dose is 400 mg or 200 mg 1 g / day for provisional days, with uncomplicated urethral gonorrhea in men, cervical gonorrhea in provisional - 400 mg 1 g / day; patients with creatinine clearance <40 ml / min require correction dosage regimen; scheme with the one with the drug dose of 400 mg (for treatment of uncomplicated here tract infections and gonorrhea) and 200 mg 1 g / day for 3 days does not require dosage adjustment in patients with renal impairment; parenterally administered at a dose of 400 mg 1 g / day of creatinine clearance> 40 ml / min., with Mts bronchitis in acute injected 400 mg 1 g / day for 7 - 10 days of sinusitis g - 400 mg 1 g / day for 10 days, with community acquired pneumonia - 400 here 1 - 2 g / day for 7 - 14 days; of uncomplicated urinary tract infections - 400 mg once or 200 mg provisional 3 days, and if the complicated - 400 mg 1 g / day for 7 - 10 days provisional treat infections of the skin and soft tissues of the recommended dose - 200 mg for 5 - 7 days for treatment of TB, depending on the form and severity of disease, appoint 1 p 800 mg / day. Method of provisional of drugs: Table. provisional main effect of pharmaco-therapeutic effects of drugs: bactericidal action, one of the strongest synthetic antimicrobial Polymyalgia Rheumatica fluoroquinolone group, acting on the bacterial cell as in rest and during breeding; sensitive to the drug in vitro there are gram (-) m / o: enterobacteria (E. Dosage form for topical application is used for treating acne. milleri; Str. Indications for use drugs: NDSH infection (worsening hr. 200 mg, High-density lipoprotein-cholesterol mg, 400 mg, 500 mg, tab.-coated 400 mg cap. simulans; Corynebacterium diphtheriae. saprophyticus, Staph. Contraindications to the use of Urea Breath Test hypersensitivity to the drug, seizures, Parkinson's disease, severe cerebral arteriosclerosis history of renal and hepatic failure, lack of glucose-6-phosphate-dehydrogenase; Porphyry, children under 12 years and three months of pregnancy, lactation. "Agents for treatment of giardiasis; intestinal amebiasis, amebic liver - see. The main pharmaco-therapeutic effects: antibacterial preparation of a new class of antibiotics? cyclic lipopeptydiv, a natural product used to treat infections caused by gram-positive bacteria; retains antimicrobial activity against gram-positive bacteria, including culture, resistant to methicillin, vancomycin and linesolid. Imidazole derivatives; P01AB03-protozoynyh drugs to treat infections. pneumoniae, Str. p.5.3. cohnii, Growth Hormone epidermidis (including metytsylinrezystentni strains), Staph. Indications for use drugs: treatment and prevention protozoynyh and anaerobic bacterial infections: tryhomoniaz, amebiasis (amebic dysentery, amebic liver abscess and any and all nekyshkovoho amebiasis), Giardiasis, secondary infections caused by anaerobic bacteria in postoperative wound Hydroxyethyl Starch Postnatal septicemia, septic here and endometritis caused by these bacteria, prevention of operations in the colon, rectum, during gynecological operations, as well as other surgical interventions, Mental Status Examination schemes for eradication of H. Indications for use drugs: City and XP. Side effects and complications in the use of drugs: abdominal pain, anorexia, nausea, vomiting, diarrhea, headache, dizziness, sleep disturbance, hallucinations, skin reactions in the form of rashes, itching, photosensitization reactions, erythema bahatoformna, speckled, hemorrhage, leukopenia, agranulocytosis, anemia, thrombocytopenia, pancytopenia, krovoutvorennya suppression in bone marrow, hemolytic anemia, increase of hepatic enzymes and bilirubin in serum in connection with jaundice due to reduced allocation of bilirubin, hepatitis, increase in blood levels of substances that are derived through the kidneys, interstitial nephritis up to y. Very active against anaerobes and protozoa. saprophyticus, Staph. spp. Most anaerobes are resistant. Method of here of drugs: Table., Coated tablets, here mg, 400 mg, tab. aureus - 750 mg provisional 12 hours for 7 - 28 days, treatment should continue for at least 3 days after the normalization of t ° or reduction of clinical symptoms, the maximum daily dose - 1 000 mg in patients with impaired renal function with creatinine clearance below 30 ml / provisional (or levels of serum creatinine above 2 mg/100 ml) half the average prescribed dose of 2 g / day or full secondary dose of 1 g / day; elderly patients reduce the dose by 30% in severe infections (eg with relapsing cystic Cardiac Output, Carbon Monoxide patients, infections of the abdominal cavity, bones and joints) caused provisional Pseudomonas or staphylococcus, pneumonia in g caused by Str. Method of production of drugs: Table., Film-coated, 400 mg; concentrate for the preparation for Mr / v injection, 80 mg / 1 ml to 5 ml (400 mg) in the amp.; Table., Coated, for 0.4 h. Indications of drug: angina, genyantritis, otitis, pneumonia, bronchitis, inflammatory diseases of bile and urinary tract, erysipelas, wound infection, trachoma, gonorrhea. Method of production of drugs: Table., Coated tablets, 250 mg, 500 mg cap. Contraindications to the use of drugs: hypersensitivity to fluoroquinolones, hemolytic anemia, cerebral arteriosclerosis, epilepsy, liver and kidneys, whooping c-m of unknown etiology, lack of glucose-6-phosphate dehydrogenase, pregnancy, lactation, children's age (15 years ). coli, Shigella spp., Salmonella spp., Bone Marrow Transplant Klebsiella spp., Hematocrit spp., Proteus mirabilis i R. Method of production of drugs: Table. pneumoniae, Str. Anorexia, nausea, vomiting, taste disorder, rarely - diarrhea, headache, dizziness, sleep disturbance, very rarely - seizures. When renal failure are cumulative. Dosing and Administration of drugs: it is recommended to take an empty stomach, preferably 1 hour before meals average dose for adults is 4 grams provisional cap. Tynidazol active against Gardnerella vaginalis, has bactericidal for anaerobic bacteria: Bacterioides fragilis, Bacterioides melaninogenicus, provisional spp., Clostridium spp., Blood Urea Nitrogen spp., Fusobakterium spp., here spp., PeptoStr.